Caprock Group LLC Takes $221,000 Position in United Therapeutics Co. (NASDAQ:UTHR)

Caprock Group LLC bought a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR) in the 2nd quarter, HoldingsChannel.com reports. The firm bought 694 shares of the biotechnology company’s stock, valued at approximately $221,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Los Angeles Capital Management LLC boosted its stake in shares of United Therapeutics by 11.8% during the 2nd quarter. Los Angeles Capital Management LLC now owns 99,328 shares of the biotechnology company’s stock valued at $31,641,000 after buying an additional 10,476 shares during the last quarter. Candriam S.C.A. boosted its stake in shares of United Therapeutics by 2,094.3% during the 2nd quarter. Candriam S.C.A. now owns 64,513 shares of the biotechnology company’s stock valued at $20,550,000 after buying an additional 61,573 shares during the last quarter. Victory Capital Management Inc. lifted its stake in United Therapeutics by 5.6% during the second quarter. Victory Capital Management Inc. now owns 153,220 shares of the biotechnology company’s stock worth $48,808,000 after purchasing an additional 8,116 shares during the last quarter. Horizon Investment Services LLC bought a new position in United Therapeutics during the second quarter worth $208,000. Finally, Hohimer Wealth Management LLC bought a new position in United Therapeutics during the second quarter worth $4,008,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Price Performance

Shares of UTHR opened at $339.12 on Friday. The firm has a market capitalization of $15.09 billion, a price-to-earnings ratio of 16.03, a price-to-earnings-growth ratio of 1.25 and a beta of 0.57. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 4.35. United Therapeutics Co. has a one year low of $208.62 and a one year high of $366.08. The stock’s fifty day moving average is $336.73 and its 200-day moving average is $287.11.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). The business had revenue of $714.90 million for the quarter, compared to analyst estimates of $691.87 million. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. United Therapeutics’s revenue for the quarter was up 19.8% on a year-over-year basis. During the same period last year, the business posted $5.24 earnings per share. Equities analysts anticipate that United Therapeutics Co. will post 24.86 EPS for the current year.

Insider Buying and Selling

In related news, CFO James Edgemond sold 7,785 shares of United Therapeutics stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the transaction, the chief financial officer now directly owns 2,615 shares of the company’s stock, valued at $947,597.55. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, CFO James Edgemond sold 7,785 shares of United Therapeutics stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the transaction, the chief financial officer now directly owns 2,615 shares of the company’s stock, valued at $947,597.55. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Martine A. Rothblatt sold 269 shares of United Therapeutics stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $348.41, for a total value of $93,722.29. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $45,293.30. The disclosure for this sale can be found here. Insiders have sold a total of 114,522 shares of company stock valued at $37,671,474 over the last three months. Company insiders own 12.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on UTHR shares. UBS Group raised their price objective on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research note on Monday, July 8th. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 2nd. Morgan Stanley cut United Therapeutics from an “overweight” rating to an “equal weight” rating and raised their target price for the company from $310.00 to $321.00 in a research note on Thursday, July 11th. Wells Fargo & Company raised their target price on United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research note on Tuesday, August 20th. Finally, Bank of America cut their target price on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a research note on Thursday, August 1st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $350.36.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.